It is tempting to speculate that anti-androgenic therapies used in the treatment of prostate cancer patients might reduce susceptibility to COVID-19 pulmonary symptoms and mortality by reducing testosterone levels and TMPRSS2 activity, but the multifactorial nature of COVID-19 infection and hormonal regulation in men does not allow to draw any definitive conclusion. Here, TMPRSS2 is linked to prostate cancer.